

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 62483

Manuscript Type: REVIEW

Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect

Non-Alcoholic Fatty Liver and Kidney Disease

Rajiv Heda, Masahiko Yazawa, Michelle Shi, Madhu Bhaskaran, Fuad Zain Aloor, Paul J Thuluvath, Sanjaya K Satapathy

Match Overview

1	Internet 67 words crawled on 04-Dec-2020 www.mdpi.com	1%
2	Internet 34 words crawled on 12-Sep-2019 tgh.amegroups.com	1%
3	Internet 27 words crawled on 06-Dec-2020 doaj.org	1%
4	Crossref 24 words Christopher D. Byrne, Giovanni Targher. "NAFLD as a c... ver of chronic kidney disease", Journal of Hepatology, 20	<1%
5	Internet 20 words crawled on 08-Nov-2015 www.science.gov	<1%
6	Crossref 18 words Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Jesu s M. Banales et al. "The effects of metabolic status on no	<1%
7	Crossref 15 words	

Non-Alcoholic Fatty Liver and Chronic Kidney Disease: Retrospect, Ir



ALL

IMAGES

VIDEOS

50,800 Results

Any time ▾

Nonalcoholic Steatohepatitis in Precision Medicine ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457694>

The link between severe **liver disease** and **kidney disease** has been known for more than a hundred years (Fabrizi et al., 2013) but the recognition that non-end stage **liver disease** can influence **kidney** function and the development of **chronic kidney disease** (CKD) has only recently come to light.

Cited by: 12

Author: John D. Clarke, Nathan J. Cherrington

Publish Year: 2015

Emerging targets and potential therapeutic agents in non ...

<https://www.sciencedirect.com/science/article/pii/S0223523420302804>

Jul 01, 2020 · Nonalcoholic Fatty Liver Disease (NAFLD) is the most common **chronic liver disease** in the world, which is characterized by **liver fat** accumulation unrelated to excessive drinking. Indeed, it attracts growing attention and becomes a global health problem.

Author: Yu Yang, Yu Zhao, Wenzhen Li, Yuya...

Publish Year: 2020

[PDF] SGLT2 inhibitors: the future for treatment of type 2 ...

<https://link.springer.com/content/pdf/10.1007/s00125-018-4678-z.pdf>

liver disease and heart failure. Keywords Diabetes mellitus . Diabetic **kidney disease** . Heart failure . **Non-alcoholic fatty liver disease** . Non-diabetic **chronic kidney disease** . Review Abbreviations DPP-4 Dipeptidyl peptidase-4 EMPA-REG OUTCOME Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients GLP-1 Glucagon ...

Cited by: 18

Author: Christoph Wanner, Nikolaus Marx

Publish Year: 2018

Pathobiology of liver fibrosis: a translational success story

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457694>

Even less is known about **disease** reversibility for other **chronic liver diseases**, but small reports cite improvements in autoimmune **liver disease**, biliary obstruction, hemochromatosis and other disorders (see ref. 10 for review). The unifying feature of these reports is the abrogation of the underlying diseases that precipitated the fibrosis.

Cited by: 649

Author: Youngmin A Lee, Michael C Wallace, Sc...

Publish Year: 2015

40,700 Results

Any time ▾

[Emerging targets and potential therapeutic agents in non ...](#)

<https://www.sciencedirect.com/science/article/pii/S0223523420302804>

Jul 01, 2020 · **Nonalcoholic Fatty Liver Disease** (NAFLD) is the most common **chronic liver disease** in the world, which is characterized by **liver fat accumulation** unrelated to excessive drinking. Indeed, it...

Author: Yu Yang, Yu Zhao, Wenzhen Li, Yuya... Publish Year: 2020

[PDF] [SGLT2 inhibitors: the future for treatment of type 2 ...](#)

<https://link.springer.com/content/pdf/10.1007/s00125-018-4678-z.pdf>

liver disease and heart failure. Keywords **Diabetes mellitus** . **Diabetic kidney disease** . **Heart failure** . **Non-alcoholic fatty liver disease** . **Non-diabetic chronic kidneydisease** .Review Abbreviations **DPP-4**...

Cited by: 19 Author: Christoph Wanner, Nikolaus Marx

Publish Year: 2018

(PDF) [Prospect of mitochondria-targeted antioxidants as ...](#)

<https://www.researchgate.net/publication/349762268...>


Mar 04, 2021 · **Prospect of mitochondria-targeted antioxidants** as hepatoprotective and anti-alcoholic **liver disease agent**. ... **chronic liver disease** [4]. ... **fatty liver disease**.


[The water extract of Sophorae tonkinensis Radix et Rhizoma](#)


Non-Alcoholic Fatty Liver Disease


Medical Condition

A condition in which fat accumulates in the liver in people who drink little or no alcohol.

 Very common (More than 3 million cases per year in US)

 Requires lab test or imaging

 Treatments can help manage condition, no known cure

 Can last several years or be lifelong

The cause of non-alcoholic fatty liver disease is not clearly understood. It is associated with obesity, insulin resistance, hyperglycemia, and high levels of fat in blood. The condition does not usually cause symptoms. In some cases, fatigue, enlarged liver, and pain in the upper right abdomen is seen. Non-alcoholic fatty liver disease has no specific treatment. It involves treating underlying conditions such as obesity.

Symptoms

Usually asymptomatic. Symptoms may include:

激活 Windows

转到“设置”以激活 Windows。



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

TOOLS ▾

Emerging targets and potential therapeutic agents in non ...

<https://www.sciencedirect.com/science/article/pii/S0223523420302804>

Jul 01, 2020 · **Nonalcoholic Fatty Liver Disease** (NAFLD) is the most common **chronic liver disease** in the world, which is characterized by **liver** fat accumulation unrelated to excessive drinking. Indeed, it attracts growing attention and becomes a global health problem.

Author: Yu Yang, Yu Zhao, Wenzhen Li, Yuyao W... **Publish Year:** 2020

[PDF] SGLT2 inhibitors: the future for treatment of type 2 ...

<https://link.springer.com/content/pdf/10.1007/s00125-018-4678-z.pdf>

liver disease and heart failure. Keywords Diabetes mellitus . Diabetic **kidney disease** . Heart failure . Non-alcoholic **fatty liver disease** . Non-diabetic **chronic** kidneydisease .Review Abbreviations DPP-4 Dipeptidyl peptidase-4 EMPA-REG OUTCOME Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients GLP-1 Glucagon ...

Cited by: 19 **Author:** Christoph Wanner, Nikolaus Marx

Publish Year: 2018

The water extract of Sophorae tonkinensis Radix et Rhizoma ...

<https://www.sciencedirect.com/science/article/pii/S094471132030101X>

Oct 01, 2020 · Introduction. Non-alcoholic **fatty liver disease** (NAFLD) is the most common cause of **chronic liver disease** in the Western countries, and the incidence is increasing year by year in the Asian-Pacific regions with the improvement of living standards (Araujo et al., 2018).It has been reported that the estimated prevalence of NAFLD in the world is approximately 25% (Araujo et al., 2018).

Author: Qing Zhao, Mengjuan Wei, Shaobo Zha... **Publish Year:** 2020

(PDF) Prospect of mitochondria-targeted antioxidants as ...

<https://www.researchgate.net/publication/349762268...>

Mar 04, 2021 · **Prospect** of mitochondria-targeted antioxidants as hepatoprotective and anti-alcoholic **liver disease** agent. ... **chronic liver disease** [4]. ... **fatty liver disease**.

(PDF) Significant Liver-Related Morbidity After Bariatric ...

<https://www.researchgate.net/publication/320133473...>

Background Non alcoholic **fatty liver disea se** (NAFLD) ... Large **prospect** ive clinical and ba sic ... atherosclerosis, cancers (breast, bowel or uterine), **chronic kidney disease**, coronary heart ...

Pro: The rationale for dietary therapy for patients with